- Insulet to Present at Upcoming Investor Conferences
- Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
- Fiasp® Rapid Acting Insulin for Adults Now Approved for Use With the Omnipod Insulin Management System Platform in the United States
- Insulet to Announce Third Quarter 2019 Financial Results on November 5, 2019
- Insulet’s Omnipod DASH™ System Now FDA Cleared as an Alternate Controller Enabled (ACE) Infusion Pump
As of last trade
Insulet Corp (PODD:NSQ) traded at 181.86, -2.88% below its 52-week high of 187.25, set on Nov 27, 2019.
70.80Jan 03 2019187.25Nov 27 2019
Markit short selling activity
|Market cap||11.37bn USD|
|EPS (TTM)||0.2542 |
Data delayed at least 15 minutes, as of Dec 09 2019 16:24 GMT.